IMMUNOCORE HOLDINGS PLC

(IMCR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
All news about IMMUNOCORE HOLDINGS PLC
05/23Medison Pharma Announces Extension of Multi-territorial Agreement with Immunocore and E..
PR
05/23Medison Pharma Announces Extension of Multi-territorial Agreement with Immunocore and E..
AQ
05/11Immunocore Holdings Q1 Net Loss Narrows as Revenue Rises
MT
05/11Immunocore Holdings plc Reports Earnings Results for the First Quarter Ended March 31, ..
CI
05/11Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update
GL
04/18IMMUNOCORE : Corporate Presentation - April 2022
PU
04/07Immunocore to present at the 21st Annual Needham Healthcare Conference
AQ
04/04IMMUNOCORE : European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unr..
PU
04/04Immunocore Wins European Regulatory Ok of Kimmtrak for Unresectable or Metastatic Uveal..
MT
04/04European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable ..
GL
04/04European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable ..
GL
04/04European Commission Approves Immunocore Holdings plc's KIMMTRAK (Tebentafusp) for the T..
CI
03/09Immunocore to present at Oppenheimer's 32nd Annual Healthcare Conference
AQ
03/03Immunocore Reports Wider Q4 Loss as Revenue Drops
MT
03/03IMMUNOCORE : Reports Full Year 2021 Financial Results and Provides Business Update - Form ..
PU
03/03Immunocore Reports Full Year 2021 Financial Results and Provides Business Update
GL
03/03Immunocore Holdings plc Reports Earnings Results for the Fourth Quarter Ended December ..
CI
03/03Immunocore Holdings plc Reports Earnings Results for the Full Year Ended December 31, 2..
CI
02/25Immunocore Says EMA Panel Backs Approval of Eye Cancer Drug
MT
02/25Immunocore receives positive CHMP opinion for KIMMTRAK® (tebentafusp) for the treatment..
AQ
02/25Immunocore Holdings plc Receives Positive CHMP Opinion for KIMMTRAK (Tebentafusp) for t..
CI
02/18IMMUNOCORE : Corporate Presentation - February 2022
PU
02/15ArriVent Biopharma Appoints Bahija Jallal to its Board of Directors
AQ
02/11Immunocore to present at the SVB Leerink Global Healthcare Conference
GL
02/11Immunocore to present at the SVB Leerink Global Healthcare Conference
GL
02/08HC Wainwright Starts Immunocore Holdings at Buy With $80 Price Target
MT
01/27Immunocore Wins US FDA Nod for Skin Cancer Drug
MT
01/26IMMUNOCORE : announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of u..
PU
01/26Health Care Stocks Catching Up With Late Market Declines
MT
01/26Health Care Stocks Putting Up Modest Gains
MT
01/26SECTOR UPDATE : Health Care
MT
01/26Health Care Stocks Climb Premarket Wednesday
MT
01/26Health Care
MT
01/26TRANSCRIPT : Immunocore Holdings plc - Special Call
CI
01/26Top Premarket Gainers
MT
01/26Immunocore Holdings Says it Gets FDA Approval for Rare Cancer Treatment; Shares Jump Pr..
MT
01/26Immunocore Gets FDA OK of Kimmtrak in Uveal Melanoma
DJ
01/26Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of ..
GL
01/26Immunocore Holdings plc Announces Approval from the United States Food and Drug Adminis..
CI
01/10IMMUNOCORE : Corporate Presentation - January 2022
PU
01/06Immunocore to present at the 40th Annual J.P. Morgan Healthcare Conference
GL
2021IMMUNOCORE : announces initial Phase 1 data of ImmTAC® candidate IMC-C103C targeting MAGE-..
PU
2021IMMUNOCORE : Initial Phase 1 Data from MAGE-A4 Program
PU
2021IMMUNOCORE : Corporate Presentation - 2021
PU
2021Immunocore Holdings Reports 'Manageable Safety Profile' From Initial Phase 1 Data of T-..
MT
2021Immunocore announces initial Phase 1 data of ImmTAC® candidate IMC-C103C targeting MAGE..
GL
2021Immunocore Announces Initial Phase 1 Data of ImmTAC® Candidate IMC-C103C Targeting Mage..
CI
2021Immunocore to present at the Jefferies London Healthcare Conference
GL
2021Immunocore Posts Narrower Q3 Loss, Lower Revenue
MT
2021INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS - Form 6-K
PU
2021Corporate Presentation - November 2021
PU
2021Immunocore Reports Third Quarter 2021 Financial Results and Provides Business Update
GL
2021Immunocore Holdings plc Reports Earnings Results for the Third Quarter and Nine Months ..
CI
2021Immunocore presents new data on tebentafusp in metastatic cutaneous melanoma (mCM) and ..
AQ
2021Immunocore Holdings plc Presents New Data on Tebentafusp in Metastatic Cutaneous Melano..
CI
2021IMMUNOCORE : to Collaborate With Medison Pharma to Expand Reach of Metastatic Uveal Melano..
MT
2021IMMUNOCORE : and Medison Pharma Partner for Future Commercialization of Tebentafusp in Can..
GL
2021Immunocore and Medison Pharma Partner for Future Commercialization of Tebentafusp in Ca..
GL
2021Immunocore and Medison Pharma Partner for Future Commercialization of Tebentafusp in Ca..
CI
2021IMMUNOCORE : announces publication of phase 3 data comparing tebentafusp with investigator..
AQ
2021Immunocore Announces Publication of Phase 3 Data Comparing tebentafusp with Investigato..
CI
2021IMMUNOCORE : Dr. Carolin Barth Joins MiroBio as CEO to Lead Precision Immunology Company F..
AQ
2021IMMUNOCORE : Reports Data From Phase 2 Trial of Tebentafusp
MT
2021Immunocore presents data at the European Society for Medical Oncology (ESMO) Congress 2..
GL
2021Immunocore Presents Data At the European Society for Medical Oncology Congress 2021 Dem..
CI
2021IMMUNOCORE : Announces Upcoming Presentations at the European Society for Medical Oncology..
AQ
2021Immunocore to present at upcoming investor conferences
GL
2021IMMUNOCORE : Tebentafusp Accepted for Marketing Authorization Review by UK Regulator
MT
2021Immunocore Announces UK's Medicines and Healthcare Products Regulatory Agency (MHRA) Ac..
GL
2021Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency Accepts M..
CI
2021An unknown buyer acquired stake in Immunocore Holdings plc from Medigene AG for $4.7 mi..
CI
2021IMMUNOCORE : EMA Committee for Medicinal Products for Human Use accepted tebentafusp Marke..
PU
2021IMMUNOCORE : Says US FDA and EU Regulators Accepted its Applications for Approval of Poten..
MT
2021Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agen..
GL
2021Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agen..
CI
1  2Next
Upcoming event on IMMUNOCORE HOLDINGS PLC